نتایج جستجو برای: melphalan

تعداد نتایج: 4419  

Journal: :Cancer research 2005
Saske Hoving Flavia Brunstein Gisela aan de Wiel-Ambagtsheer Sandra T van Tiel Gert de Boeck Ernst A de Bruijn Alexander M M Eggermont Timo L M ten Hagen

The cytokine interleukin 2 (IL-2) is a mediator of immune cell activation with some antitumor activity, mainly in renal cell cancer and melanoma. We have previously shown that tumor necrosis factor (TNF)-alpha has strong synergistic antitumor activity in combination with chemotherapeutics in the isolated limb perfusion (ILP) setting based on a TNF-mediated enhanced tumor-selective uptake of the...

Journal: :Cancer research 1982
G D Griffin B A Owen C E Atchley G D Novelli A Solomon

The effect of melphalan on immunoglobulin G (IgG) production by a human lymphoblastoid cell line (BF) was studied. The amount of secreted IgG and the percentage of cells containing cytoplasmic IgG were measured by immunoassay and cytofluorometry, respectively. Dose-response studied indicated that melphalan concentrations of 2 X 10(-8) M had no effect, while concentrations of 8 X 10(-7) M were t...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2013
Dharminder Chauhan Arghya Ray Kristina Viktorsson Jack Spira Claudia Paba-Prada Nikhil Munshi Paul Richardson Rolf Lewensohn Kenneth C Anderson

PURPOSE The alkylating agent melphalan prolongs survival in patients with multiple myeloma; however, it is associated with toxicities and development of drug-resistance. Here, we evaluated the efficacy of melphalan-flufenamide (mel-flufen), a novel dipeptide prodrug of melphalan in multiple myeloma. EXPERIMENTAL DESIGN Multiple myeloma cell lines, primary patient cells, and the human multiple...

Journal: :Blood 2006
Thierry Facon Jean-Yves Mary Brigitte Pégourie Michel Attal Marc Renaud Alain Sadoun Laurent Voillat Véronique Dorvaux Cyrille Hulin Gérard Lepeu Jean-Luc Harousseau Jean-Paul Eschard Augustin Ferrant Michel Blanc Frédéric Maloisel Hubert Orfeuvre Jean-François Rossi Isabelle Azaïs Mathieu Monconduit Philippe Collet Bruno Anglaret Ibrahim Yakoub-Agha Marc Wetterwald Houchingue Eghbali Marie-Christine Vekemans Hervé Maisonneuve Jacques Troncy Bernard Grosbois Chantal Doyen Antoine Thyss Jérome Jaubert Philippe Casassus Béatrice Thielemans Régis Bataille

Dexamethasone alone increases life expectancy in patients with relapsed multiple myeloma (MM); however, no large randomized study has compared dexamethasone and dexamethasone-based regimens with standard melphalan-prednisone in newly diagnosed MM patients ineligible for high-dose therapy. In the Intergroupe Francophone du Myélome (IFM) 95-01 trial, 488 patients aged 65 to 75 years were randomiz...

Journal: :Cancer research 1990
S C Barranco C M Townsend B Weintraub E G Beasley K K MacLean J Shaeffer N H Liu K Schellenberg

A clone of a human gastric carcinoma cell line was used to determine whether cells which had survived a treatment with Melphalan would express altered survival responses when treated again with this agent 1 week or more later. Cells were treated for 1 h each week with 2 micrograms/ml (99% lethal dose). After the first Melphalan treatment, the cells exhibited a 10-fold reduction in sensitivity t...

Journal: :Journal of immunology 2015
Xiaoyun Lu Zhi-Chun Ding Yang Cao Chufeng Liu Tsadik Habtetsion Miao Yu Henrique Lemos Huda Salman Hongyan Xu Andrew L Mellor Gang Zhou

In recent years, the immune-potentiating effects of some widely used chemotherapeutic agents have been increasingly appreciated. This provides a rationale for combining conventional chemotherapy with immunotherapy strategies to achieve durable therapeutic benefits. Previous studies have implicated the immunomodulatory effects of melphalan, an alkylating agent commonly used to treat multiple mye...

2006
William A. Redwood Michael Colvin

The in vitro transport of L-p-(di-2-Chloroethylamino)[14C]phe nylalanine by i.p. grown mouse L1210 leukemias has been studied in melphalan-sensitive and melphalan-resistant cell populations. As has been reported previously, uptake of the drug is a temperature-sensitive, partly sodium-dependent, ac tive process with cell:medium accumulation in excess of 5:1 at 370 and a process which is competit...

2016
An- Ning Chao Ling-Yuh Kao Laura Liu Nan-Kai Wang

BACKGROUND Controlling retinoblastoma with seeding is challenging despite advances in treatment modalities. Intravitreal melphalan is an alternative to external beam radiation or enucleation for recurrent or refractory vitreous seeds. Significant ocular side effects following intravitreal melphalan injections are uncommon. Complications have been reported in eyes receiving higher concentrations...

Journal: :Nuclear medicine and biology 2014
S Gouard A Pallardy J Gaschet A Faivre-Chauvet F Bruchertseifer A Morgenstern C Maurel E Matous F Kraeber-Bodéré F Davodeau M Chérel

INTRODUCTION Multiple myeloma (MM) is a B-cell malignancy of terminally differentiated plasma cells within the bone marrow. Despite intense research to develop new treatments, cure is almost never achieved. Alpha-radioimmunotherapy (RIT) has been shown to be effective in vivo in a MM model. In order to define where alpha-RIT stands in MM treatment, the aim of this study was to compare Melphalan...

Journal: :Cancer research 1985
P J Tofilon I Basic L Milas

The ability of the in vitro sister chromatid exchange (SCE) assay to predict in vivo tumor drug sensitivity was investigated using a spontaneous hepatocarcinoma in C3Hf/Kam mice and 3 chemotherapeutic agents: melphalan; cis-platinum; and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). For hepatocarcinoma cells grown in monolayer culture, melphalan was the most efficient at inducing SCEs, and BCNU,...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید